Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.67 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.67 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.67 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.67 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.67 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.67 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.67 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.67 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.67 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.60 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ym-90K SCHEMBL29798088 | 0.81 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Ym-90K SCHEMBL2049549 | 0.81 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8911643 | 0.81 | GRIK1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL13227266 | 0.80 | SLC22A6 (0.71) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Ym-90K SCHEMBL29384442 | 0.80 | GRIA1 (0.97) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Ym-90K SCHEMBL1055529 | 0.80 | GRIA1 (0.97) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Ym-90K SCHEMBL678466 | 0.80 | GRIA1 (0.97) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Water SCHEMBL8145177 | 0.78 | GRIK1 (0.67) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Water SCHEMBL9423395 | 0.78 | GRIK1 (0.67) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8911406 | 0.77 | GRIK1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238654-B2 | Singleton inhibitors of sumoylation enzymes and methods for their use | CITY OF HOPE (US) | 2016-01-19 | — | — | US | disclosed |
| US-20130317101-A1 | SINGLETON INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE | Sanford-Burnham Medical Research Institute at Lake Nona (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130245032-A1 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE | Sanford-Burnham Medical Research Institute at Lake Nona (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2012064897-A2 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE | CHEN YUAN (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064898-A1 | SINGLETON INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE | CHEN YUAN (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317101-A1 | SINGLETON INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE | SUMO1, SUMO2, SAE1 | GRIA1 3524/4885GRIA2 4122/4885GRIA3 3887/4885 |
| US-20130245032-A1 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE | SUMO1, SUMO2, SAE1 | GRIA1 3043/4885GRIA2 3399/4885GRIA3 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.